Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this pharmacokinetics study is to compare the maximum concentration
level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the end of
a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end
of a standard 1-hour infusion with the goal of determining whether lengthening the infusion
in patients with low/sarcopenic SMA normalizes the levels to those of patients with normal
SMA.